Immuneering Completes Oversubscribed $62 Million Series B Financing

By January 5, 2021News

Financing to support advancement of Immuneering’s lead drug programs targeting cancers driven by alterations in the RAS/MAPK pathway and pipeline development of earlier programs in neuroscience and immuno-oncology.